| 1. Executive Summary |
| 2. Global Antibiotics Market Introduction |
| 2.1. Global Antibiotics Market – Taxonomy |
| 2.2. Global Antibiotics Market –Definitions |
| 2.2.1. By Drug Class |
| 2.2.2. By Action Mechanism |
| 2.2.3. By Spectrum |
| 2.2.4. By Region |
| 3. Global Antibiotics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Antibiotics Market Dynamic Factors – Impact Analysis |
| 3.6. Global Antibiotics Market – Competition Landscape |
| 4. Global Antibiotics Market Analysis,2017-2021 and Forecast, 2022-2028 |
| 4.1. Market Analysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Antibiotics Market, By Drug Class, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1. Cephalosporins |
| 5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Penicillins |
| 5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Fluroquinilones |
| 5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Macrolides |
| 5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Carbapenems |
| 5.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Aminoglycosides |
| 5.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Sulfonamides |
| 5.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| Market Opportunity Analysis |
| 5.8. Others |
| 5.8.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6. Global Antibiotics Market Forecast, By Action Mechanism, 2017-2021 and Forecast, 2021 – 2027 (Revenue, USD Mn) |
| 6.1. Cell Wall Synthesis Inhibitors |
| 6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Protein Synthesis Inhibitors |
| 6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. DNA Synthesis Inhibitors |
| 6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. RNA Synthesis Inhibitors |
| 6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Mycolic Acid Inhibitors |
| 6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7. Global Antibiotics Market, By Spectrum, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1. Broad-spectrum Antibiotics |
| 7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Narrow-spectrum Antibiotics |
| 7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Antibiotics Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Region, 2022-2028 |
| 9. North America Antibiotics MarketAnalysis,2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Cephalosporins |
| 9.1.2. Penicillins |
| 9.1.3. Fluroquinilones |
| 9.1.4. Macrolides |
| 9.1.5. Carbapenems |
| 9.1.6. Aminoglycosides |
| 9.1.7. Sulfonamides |
| 9.1.8. Others |
| 9.2. Action Mechanism Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.2.1. Cell Wall Synthesis Inhibitors |
| 9.2.2. Protein Synthesis Inhibitors |
| 9.2.3. DNA Synthesis Inhibitors |
| 9.2.4. RNA Synthesis Inhibitors |
| 9.2.5. Mycolic Acid Inhibitors |
| 9.2.6. Others |
| 9.3. Spectrum Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Broad-spectrum Antibiotics |
| 9.3.2. Narrow-spectrum Antibiotics |
| 9.4. Country Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2022-2028 |
| 9.6. North America Antibiotics Market Dynamics – Trends |
| 10. Europe Antibiotics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Cephalosporins |
| 10.1.2. Penicillins |
| 10.1.3. Fluroquinilones |
| 10.1.4. Macrolides |
| 10.1.5. Carbapenems |
| 10.1.6. Aminoglycosides |
| 10.1.7. Sulfonamides |
| 10.1.8. Others |
| 10.2. Action Mechanism Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Cell Wall Synthesis Inhibitors |
| 10.2.2. Protein Synthesis Inhibitors |
| 10.2.3. DNA Synthesis Inhibitors |
| 10.2.4. RNA Synthesis Inhibitors |
| 10.2.5. Mycolic Acid Inhibitors |
| 10.2.6. Others |
| 10.3. Spectrum Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Broad-spectrum Antibiotics |
| 10.3.2. Narrow-spectrum Antibiotics |
| 10.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Poland |
| 10.4.8. Rest of Europe |
| 10.5. Europe Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2022-2028 |
| 10.6. Europe Antibiotics Market Dynamics – Trends |
| 11. Asia-Pacific Antibiotics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 11.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Cephalosporins |
| 11.1.2. Penicillins |
| 11.1.3. Fluroquinilones |
| 11.1.4. Macrolides |
| 11.1.5. Carbapenems |
| 11.1.6. Aminoglycosides |
| 11.1.7. Sulfonamides |
| 11.1.8. Others |
| 11.2. Action Mechanism Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Cell Wall Synthesis Inhibitors |
| 11.2.2. Protein Synthesis Inhibitors |
| 11.2.3. DNA Synthesis Inhibitors |
| 11.2.4. RNA Synthesis Inhibitors |
| 11.2.5. Mycolic Acid Inhibitors |
| 11.2.6. Others |
| 11.3. Spectrum Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Broad-spectrum Antibiotics |
| 11.3.2. Narrow-spectrum Antibiotics |
| 11.4. Country Analysis2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Japan |
| 11.4.2. China |
| 11.4.3. India |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2022-2028 |
| 11.6. Asia-Pacific Antibiotics Market Dynamics – Trends |
| 12. Latin America Antibiotics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 12.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Cephalosporins |
| 12.1.2. Penicillins |
| 12.1.3. Fluroquinilones |
| 12.1.4. Macrolides |
| 12.1.5. Carbapenems |
| 12.1.6. Aminoglycosides |
| 12.1.7. Sulfonamides |
| 12.1.8. Others |
| 12.2. Action Mechanism Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Cell Wall Synthesis Inhibitors |
| 12.2.2. Protein Synthesis Inhibitors |
| 12.2.3. DNA Synthesis Inhibitors |
| 12.2.4. RNA Synthesis Inhibitors |
| 12.2.5. Mycolic Acid Inhibitors |
| 12.2.6. Others |
| 12.3. Spectrum Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Broad-spectrum Antibiotics |
| 12.3.2. Narrow-spectrum Antibiotics |
| 12.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2022-2028 |
| 12.6. Latin America Antibiotics Market Dynamics – Trends |
| 13. Middle East and Africa Antibiotics Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 13.1. By Drug Class Analysis 2017-2021 and Forecast 2022-2028by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Cephalosporins |
| 13.1.2. Penicillins |
| 13.1.3. Fluroquinilones |
| 13.1.4. Macrolides |
| 13.1.5. Carbapenems |
| 13.1.6. Aminoglycosides |
| 13.1.7. Sulfonamides |
| 13.1.8. Others |
| 13.2. Action Mechanism Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Cell Wall Synthesis Inhibitors |
| 13.2.2. Protein Synthesis Inhibitors |
| 13.2.3. DNA Synthesis Inhibitors |
| 13.2.4. RNA Synthesis Inhibitors |
| 13.2.5. Mycolic Acid Inhibitors |
| 13.2.6. Others |
| 13.3. Spectrum Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Broad-spectrum Antibiotics |
| 13.3.2. Narrow-spectrum Antibiotics |
| 13.4. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Antibiotics Market – Opportunity Analysis Index, By Drug Class, Action Mechanism, Spectrum, and Country, 2022-2028 |
| 13.6. MEA Antibiotics Market Dynamics – Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Action Mechanism& Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Abbott Laboratories |
| 14.2.2. Allergan Plc. |
| 14.2.3. F. Hoffmann-La Roche Ltd. |
| 14.2.4. GlaxoSmithKline plc |
| 14.2.5. Merck & Co. Inc. |
| 14.2.6. Mylan N.V. |
| 14.2.7. Novartis International AG (Sandoz) |
| 14.2.8. Pfizer Inc. |
| 14.2.9. Sanofi |
| 14.2.10. Teva Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
Request Sample
Request Methodology
